Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5672946 | Journal of Virological Methods | 2017 | 16 Pages |
Abstract
CDV growth in VERO cells was inhibited by ribavirin, by boceprevir and by a combination of the two molecules at non-cytotoxic concentrations, as evaluated by end-point viral titration in cell monolayers and by quantification of viral RNA using quantitative RT-PCR. By end-point titration, a statistically significant reduction in CDV replication was observed only using ribavirin and boceprevir in combination. By quantitative RT-PCR, a significant reduction of viral growth was observed either in cells treated with ribavirin or boceprevir or with both the two molecules. The association of ribavirin or boceprevir was able to decrease CDV growth by up to 3.4458 logs with respect to untreated infected cells, chiefly at the highest virus dilutions. The results obtained in this study may constitute an important basis for the development of CDV therapies.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Gianvito Lanave, Alessandra Cavalli, Vito Martella, Tommaso Fontana, Ruggero Losappio, Maria Tempesta, Nicola Decaro, Domenico Buonavoglia, Michele Camero,